Aortic valve stenosis and coronary artery disease share pathophysiological links, including chronic inflammation and atherosclerotic processes, suggesting they may benefit from similar clinical therapy.
Aortic valve stenosis (AVS), including a range of disorder severities, from mild leaflet thickening without valve obstruction, 'aortic sclerosis', to severe calcific aortic stenosis, is a progressive, active process of valve modification, mediating by chronic inflammation (similar to atherosclerosis for cardiovascular risk factors) and biological features. AVS is the expression of early tissue damage due to endothelial damage and oxidative, inflammatory processes, and appears as a surrogate marker for cardiovascular events associated with coronary artery disease (CAD). AVS progression correlates with coronary artery risk factors, such as hypertension, age and cholesterol, and a quantitative evaluation of valve and coronary calcium score comprises a useful marker for cardiovascular prognosis. The low concordance of AVS with CAD appears to be due to other genetic or metabolic factors more specific for calcification processes. Moreover, both pathologies appear to be included within atherosclerotic disease and may be the object of the same clinical therapy and prevention.
Mazzone et al. (Sat,) conducted a review in Aortic valve stenosis and coronary artery disease. Aortic valve stenosis and coronary artery disease share pathophysiological links, including chronic inflammation and atherosclerotic processes, suggesting they may benefit from similar clinical therapy.